GB201803340D0 - Compounds - Google Patents

Compounds

Info

Publication number
GB201803340D0
GB201803340D0 GBGB1803340.7A GB201803340A GB201803340D0 GB 201803340 D0 GB201803340 D0 GB 201803340D0 GB 201803340 A GB201803340 A GB 201803340A GB 201803340 D0 GB201803340 D0 GB 201803340D0
Authority
GB
United Kingdom
Prior art keywords
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1803340.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Sussex
Original Assignee
University of Sussex
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Sussex filed Critical University of Sussex
Priority to GBGB1803340.7A priority Critical patent/GB201803340D0/en
Publication of GB201803340D0 publication Critical patent/GB201803340D0/en
Priority to MX2020009097A priority patent/MX2020009097A/es
Priority to PL19710107.4T priority patent/PL3759092T3/pl
Priority to US16/970,394 priority patent/US11298345B2/en
Priority to CA3091783A priority patent/CA3091783A1/en
Priority to BR112020017739-3A priority patent/BR112020017739A2/pt
Priority to JP2020544266A priority patent/JP7225255B2/ja
Priority to ES19710107T priority patent/ES2970784T3/es
Priority to RU2020127537A priority patent/RU2020127537A/ru
Priority to CN201980016394.0A priority patent/CN112004811B/zh
Priority to KR1020207025799A priority patent/KR102821949B1/ko
Priority to AU2019226718A priority patent/AU2019226718C1/en
Priority to EP19710107.4A priority patent/EP3759092B1/en
Priority to KR1020257019599A priority patent/KR20250093578A/ko
Priority to FIEP19710107.4T priority patent/FI3759092T3/fi
Priority to DK19710107.4T priority patent/DK3759092T3/da
Priority to NZ767186A priority patent/NZ767186B2/en
Priority to PCT/GB2019/050578 priority patent/WO2019166822A1/en
Priority to US17/687,296 priority patent/US12383540B2/en
Priority to US19/238,079 priority patent/US20250375432A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB1803340.7A 2018-03-01 2018-03-01 Compounds Ceased GB201803340D0 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
GBGB1803340.7A GB201803340D0 (en) 2018-03-01 2018-03-01 Compounds
PCT/GB2019/050578 WO2019166822A1 (en) 2018-03-01 2019-03-01 Compounds that modulates ampa receptor function
RU2020127537A RU2020127537A (ru) 2018-03-01 2019-03-01 Соединения, которые модулируют функцию ampa-рецептора
KR1020207025799A KR102821949B1 (ko) 2018-03-01 2019-03-01 Ampa 수용체 기능을 조절하는 화합물
US16/970,394 US11298345B2 (en) 2018-03-01 2019-03-01 Compounds that modulates AMPA receptor function
CA3091783A CA3091783A1 (en) 2018-03-01 2019-03-01 Compounds that modulates ampa receptor function
BR112020017739-3A BR112020017739A2 (pt) 2018-03-01 2019-03-01 Compostos que modulam a função do receptor ampa
JP2020544266A JP7225255B2 (ja) 2018-03-01 2019-03-01 Ａｍｐａ受容体機能を調節する化合物
ES19710107T ES2970784T3 (es) 2018-03-01 2019-03-01 Compuestos que modulan la función del receptor de AMPA
MX2020009097A MX2020009097A (es) 2018-03-01 2019-03-01 Compuestos que modulan la funcion del receptor de ampa.
CN201980016394.0A CN112004811B (zh) 2018-03-01 2019-03-01 调节ampa受体功能的化合物
PL19710107.4T PL3759092T3 (pl) 2018-03-01 2019-03-01 Związki modulujące funkcję receptora ampa
AU2019226718A AU2019226718C1 (en) 2018-03-01 2019-03-01 Compounds that modulates AMPA receptor function
EP19710107.4A EP3759092B1 (en) 2018-03-01 2019-03-01 Compounds that modulates ampa receptor function
KR1020257019599A KR20250093578A (ko) 2018-03-01 2019-03-01 Ampa 수용체 기능을 조절하는 화합물
FIEP19710107.4T FI3759092T3 (fi) 2018-03-01 2019-03-01 Yhdisteitä, jotka moduloivat ampa-reseptoritoimintaa
DK19710107.4T DK3759092T3 (da) 2018-03-01 2019-03-01 Forbindelser, der modulerer ampa-receptorfunktion
NZ767186A NZ767186B2 (en) 2019-03-01 Compounds that modulates ampa receptor function
US17/687,296 US12383540B2 (en) 2018-03-01 2022-03-04 Compounds that modulates AMPA receptor function
US19/238,079 US20250375432A1 (en) 2018-03-01 2025-06-13 Compounds that modulates ampa receptor function

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1803340.7A GB201803340D0 (en) 2018-03-01 2018-03-01 Compounds

Publications (1)

Publication Number Publication Date
GB201803340D0 true GB201803340D0 (en) 2018-04-18

Family

ID=61903711

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1803340.7A Ceased GB201803340D0 (en) 2018-03-01 2018-03-01 Compounds

Country Status (16)

Country Link
US (3) US11298345B2 (enExample)
EP (1) EP3759092B1 (enExample)
JP (1) JP7225255B2 (enExample)
KR (2) KR20250093578A (enExample)
CN (1) CN112004811B (enExample)
AU (1) AU2019226718C1 (enExample)
BR (1) BR112020017739A2 (enExample)
CA (1) CA3091783A1 (enExample)
DK (1) DK3759092T3 (enExample)
ES (1) ES2970784T3 (enExample)
FI (1) FI3759092T3 (enExample)
GB (1) GB201803340D0 (enExample)
MX (1) MX2020009097A (enExample)
PL (1) PL3759092T3 (enExample)
RU (1) RU2020127537A (enExample)
WO (1) WO2019166822A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201702221D0 (en) 2017-02-10 2017-03-29 Univ Of Sussex Compounds
GB201803340D0 (en) 2018-03-01 2018-04-18 Univ Of Sussex Compounds

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW575561B (en) 1999-03-25 2004-02-11 Hoffmann La Roche 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives
WO2001096308A1 (en) 2000-06-12 2001-12-20 Eisai Co., Ltd. 1,2-dihydropyridine compounds, process for preparation of the same and use thereof
RU2279428C2 (ru) 2000-09-18 2006-07-10 Эйсай Ко., Лтд. Производные пиридазинона и триазинона и их применение в качестве фармацевтических препаратов
AU2003302027A1 (en) 2002-11-21 2004-06-15 Vicore Pharma Ab New tricyclic angiotensin ii agonists
WO2006109056A1 (en) 2005-04-12 2006-10-19 Vicore Pharma Ab New tricyclic angiotensin ii agonists
TW200812975A (en) 2006-03-20 2008-03-16 Glaxo Group Ltd Compounds which potentiate AMPA receptor and uses thereof in medicine
ATE543798T1 (de) 2006-04-24 2012-02-15 Lilly Co Eli Cyclohexyl-substituierte pyrrolidinone als hemmer von 11-beta-hydroxysteroiddehydrogenase 1
TW200817385A (en) 2006-07-04 2008-04-16 Organon Nv Heterocyclic derivatives
EP2086643B1 (en) 2006-11-03 2011-03-23 Glaxo Group Limited Compounds which potentiate ampa receptor and uses thereof in medicine
GB0711088D0 (en) * 2007-06-08 2007-07-18 Glaxo Group Ltd Compounds
GB0711089D0 (en) 2007-06-08 2007-07-18 Glaxo Group Ltd Compounds
JP5451611B2 (ja) 2007-07-26 2014-03-26 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１のサイクリックインヒビター
NZ584098A (en) 2007-09-20 2012-05-25 Cortex Pharma Inc 3-substituted 1,2,3-triazin-4-one's and 3-substituted 1,3-pyrimidinone's for enhancing glutamatergic synaptic responses
GB0721094D0 (en) 2007-10-26 2007-12-05 Glaxo Group Ltd Compounds
TW200934497A (en) 2007-11-13 2009-08-16 Organon Nv Heterocyclic derivatives
TW201004945A (en) 2008-05-01 2010-02-01 Vitae Pharmaceuticals Inc Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
TW201012803A (en) 2008-06-06 2010-04-01 Organon Nv Heterocyclic derivatives
TW201031649A (en) * 2008-12-02 2010-09-01 Organon Nv 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives
AU2010264095B2 (en) 2009-06-26 2013-07-11 Biogen Ma Inc. Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof
WO2011132051A2 (en) * 2010-04-19 2011-10-27 Glenmark Pharmaceuticals S.A. Tricycle compounds as phosphodiesterase-10 inhibitors
UY33930A (es) 2011-03-04 2012-10-31 Novartis Ag Inhibidores novedosos de quinasas
GB201702221D0 (en) 2017-02-10 2017-03-29 Univ Of Sussex Compounds
GB201803340D0 (en) 2018-03-01 2018-04-18 Univ Of Sussex Compounds

Also Published As

Publication number Publication date
US20250375432A1 (en) 2025-12-11
EP3759092A1 (en) 2021-01-06
EP3759092B1 (en) 2023-12-20
CN112004811A (zh) 2020-11-27
ES2970784T3 (es) 2024-05-30
AU2019226718A1 (en) 2020-09-03
JP7225255B2 (ja) 2023-02-20
PL3759092T3 (pl) 2024-04-08
BR112020017739A2 (pt) 2020-12-22
AU2019226718A8 (en) 2020-09-24
JP2021515749A (ja) 2021-06-24
DK3759092T3 (da) 2024-01-22
KR20250093578A (ko) 2025-06-24
WO2019166822A1 (en) 2019-09-06
US20230000847A1 (en) 2023-01-05
FI3759092T3 (fi) 2024-01-18
AU2019226718C1 (en) 2024-01-11
KR20200128032A (ko) 2020-11-11
AU2019226718B2 (en) 2023-09-28
RU2020127537A (ru) 2022-04-26
CN112004811B (zh) 2023-09-22
US20210113539A1 (en) 2021-04-22
CA3091783A1 (en) 2019-09-06
MX2020009097A (es) 2020-10-08
NZ767186A (en) 2025-02-28
US12383540B2 (en) 2025-08-12
US11298345B2 (en) 2022-04-12
KR102821949B1 (ko) 2025-06-16

Similar Documents

Publication Publication Date Title
SG11202010450VA (en) Compounds
GB202105206D0 (en) Compounds
GB201805174D0 (en) Compounds
GB201807924D0 (en) Compounds
GB201810581D0 (en) Compounds
GB201808093D0 (en) Compounds
PT3810633T (pt) Compostos
GB201812382D0 (en) Compounds
GB201814151D0 (en) Compounds
GB201820887D0 (en) Compounds
GB201809102D0 (en) Compounds
GB201818649D0 (en) Compounds
GB201818651D0 (en) Compounds
GB201817083D0 (en) Compounds
GB201814167D0 (en) Compounds
GB201810071D0 (en) Compounds
GB201801130D0 (en) Compounds
GB201801128D0 (en) Compounds
GB201820989D0 (en) Compounds
GB201819102D0 (en) Compounds
GB201818927D0 (en) Compounds
GB201818698D0 (en) Compounds
GB201818410D0 (en) Compounds
GB201817342D0 (en) Compounds
GB201817292D0 (en) Compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)